Wealth Enhancement Advisory Services’s abrdn Life Sciences Investors HQL Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$214K	Buy	12,301 +1,615	+15%	+$32.7K	﹤0.01%	3685
2026 Q2	$217K	Sell	10,686 -1	-0%	-$18	﹤0.01%	3510
2026 Q1	$180K	Buy	+10,687	New	+$179K	﹤0.01%	3170
2024 Q4	–	Sell	-15,932	Closed	-$240K	–	3030
2024 Q3	$240K	Sell	15,932 -3,851	-19%	-$58.3K	﹤0.01%	2332
2024 Q2	$280K	Sell	19,783 -661	-3%	-$8.94K	﹤0.01%	2030
2024 Q1	$279K	Buy	20,444 +991	+5%	+$13.7K	﹤0.01%	1973
2023 Q4	$262K	Sell	19,453 -1,427	-7%	-$17.6K	﹤0.01%	1907
2023 Q3	$260K	Buy	+20,880	New	+$275K	﹤0.01%	1829

Other funds holding HQL

PMG Family Office Plano, Texas $108M AUM 8.93% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.95B AUM 25.45% 1-Year Est. Return

Decision Investments San Diego, California $110M AUM 52.83% 1-Year Est. Return

Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return

Wealthcare Advisory Partners West Chester, Pennsylvania $5.9B AUM 14.62% 1-Year Est. Return

Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Highline Wealth Partners Sherman Oaks, California $527M AUM 13.86% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Wealth Enhancement Advisory Services's HQL Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its abrdn Life Sciences Investors (HQL) stake by 15% in Q3 2026, buying an estimated $32.7K and bringing the position to 12,301 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #3685.

Wealth Enhancement Advisory Services first reported a position in HQL in Q3 2023 and has held it in 8 quarters since. The position peaked at $280K in Q2 2024. 11 funds tracked by Wall St. Rank hold HQL as of Q3 2026.

Wealth Enhancement Advisory Services held 12,301 shares of abrdn Life Sciences Investors worth $214K as of Q3 2026.
Wealth Enhancement Advisory Services bought 1,615 abrdn Life Sciences Investors shares in Q3 2026, an estimated $32.7K.
abrdn Life Sciences Investors made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3685 holding.
Wealth Enhancement Advisory Services first reported a position in abrdn Life Sciences Investors in Q3 2023 and has held it in 8 quarters since.
Wealth Enhancement Advisory Services's abrdn Life Sciences Investors position peaked at $280K in Q2 2024.
11 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.